The pharmaceutical industry has always been dependent on technological innovation for success. In recent years, the risk and reward of this innovation has increased markedly as the costs and uncertainty of developing new drugs have mushroomed. The process of creating drugs is long and arduous. Managing how new pharmaceuticals are...
Merck & Co., Inc. develops, manufactures, and markets innovative products to improve human and animal health. Merck ships confidential documents regarding its late-stage clinical drug trials to physicians around the country during the trials' course. Merck relies on the physicians to protect the documents' confidentiality after delivery. Merck evaluated Microsoft...
MaybachFinancial.com is one of the fastest growingindependent and unbiased research firms in the world. Through our numerouspartnerships with many of the top investment minds in the world, we provideresearch on companies making a move in the markets. Investors seekinggenuine analyst opinions on their investments for Bristol-Myers SquibbCompany (NYSE: BMY), Merck...
SAN FRANCISCO, Aug. 20 /PRNewswire/ -- Emerging therapeutic strategies for Alzheimer's disease is the focus of the most recent edition of Neurotech Insights, the leading monthly industry newsletter covering drugs, devices and diagnostics for the brain and nervous system. This month's feature article reviews the competing hypotheses...
- First Product Developed from the VisEn-Merck & Co., Inc. Biomarker Imaging Program - - Expands VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio and Broadens Applications in Key Areas of Disease Research and Drug Development - BEDFORD, Mass., Aug. 19 /PRNewswire/ -- VisEn Medical, Inc.,...
WHITEHOUSE STATION, N.J. -- Merck & Co. Inc. today announced the winners of the second annual Merck Index Women in Chemistry Scholarship program. The program is designed to foster support for women choosing to pursue advanced degrees in medicinal or synthetic organic chemistry. "We are pleased to be...
Second Phase 2 clinical trial underway this quarter to evaluate oral deforolimus CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a randomized, multi-center, Phase 2 clinical trial to evaluate the safety and efficacy of oral deforolimus, its investigational mTOR inhibitor, in patients with...
SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2008. Total revenues in the second quarter of 2008 were $2.6 million, compared to $4.8 million in the second quarter of 2007, and included $2.0 million...
Efficacy and Tolerability Profile Consistent With Data Seen in Approved Treatment-Experienced Indication WHITEHOUSE STATION, N.J. -- ISENTRESS([R]) raltegravir, Merck & Co., Inc.'s first-in-class integrase inhibitor, in combination with two other anti-HIV medicines, reduced HIV viral load to undetectable levels (less than 50 copies/mL) in 83 percent of previously...
BERKELEY, Calif. & WHITEHOUSE STATION, N.J. -- Dynavax Technologies Corporation (Nasdaq:DVAX) and Merck & Co., Inc. announced today top-line immunogenicity results from a Phase 3 clinical trial comparing HEPLISAV[TM], an investigational hepatitis B virus HBV vaccine, to a currently marketed HBV vaccine, Engerix-B([R] (1)). The study achieved its primary endpoint....
MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ -- MicroDose Technologies Inc. MicroDose today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose's dry powder inhaler DPI technology...
CHICAGO, Aug. 4 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/080408A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts...
- Agreement Includes Countries in Latin America and the Asia-Pacific Region - - Under Agreement, Gilead Will Lead Regulatory and Distribution Processes - FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J. -- Gilead Sciences, Inc. (Nasdaq:GILD) and Merck & Co., Inc. (NYSE:MRK) today announced that the companies...
SANTA CLARA, Calif. -- XenoPort, Inc. (Nasdaq:XNPT) announced today the appointment of Per G. H. Lofberg to its board of directors. Mr. Lofberg is currently Chairman and a Managing Director of Pharma Capital Ventures. "We are pleased to welcome Per to the XenoPort board," said Ronald W. Barrett,...
PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Covance Inc. , a leading provider of drug development services, today announced that its central laboratory services received Merck & Co., Inc.'s Outstanding Strategic Collaboration Award. Covance Central Laboratory Services is one of only 12 suppliers who were selected from thousands...
Advances milestone in global collaboration with Merck & Co., Inc. CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has initiated a Phase 2 clinical trial to examine the efficacy and safety of oral deforolimus, its investigational mTOR inhibitor, in patients with advanced breast cancer....
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/b52ba1/merck_co_partner) has announced the addition of the "Merck & Co Partnering Guide 2008" company profile to their offering. The Merck & Co Partnering Guide 2008 provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma...
Ambrilia Biopharma Inc. (TSX: AMB) today announced that it was advised by Merck & Co, Inc., that the HIV protease inhibitor PPL-100, also known as MK-8122, has been placed on a development hold pending outcome of additional basic science efforts to evaluate other PL-100 prodrugs and formulations options. Merck's decision...
New research offers more evidence that a new AIDS drug brings significant benefits to patients who have failed other treatments. The drug, known as raltegravir Isentress, almost doubles the likelihood that patients will beat back the AIDS virus despite being immune to other medications, according to a study in the...
Robert J. Byrnes, 86, of Berwyn, a retired corporate vice president, died of a stroke Sunday at his home. In 1988, Mr. Byrnes retired as a corporate vice president of SmithKline Beecham, now GlaxoSmithKline. At the time, he was also president of the pharmaceutical company's chemical division. He had supervised...
Choose up to 5" more legroom with Economy Plus. Starting at $14.
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
